Detalhe da pesquisa
1.
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.
Br J Haematol
; 201(4): 682-689, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36822820
2.
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Br J Haematol
; 201(1): 162-167, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720464
3.
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.
Hemasphere
; 6(6): e738, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35651713
4.
A same-day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3-mimetic targeting in multiple myeloma cells.
EJHaem
; 2(1): 40-47, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35846088